TRIO Pharmaceuticals is a cancer immunotherapeutics company pioneering bispecific antibodies for the treatment of cancer with unprecedented potency and selectivity. TRIO's innovative antibody drugs directly stop tumor growth without affecting normal cells and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. TRIO is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells. TRIO has an experienced team that has developed first-in-class FDA-approved drugs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/03/24 | $3,100,000 | Pre-Series A |
Friedman BioVentures Life Science Angels Myeloma Investment Fund NuFund Venture Group | undisclosed |
